[{"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of dark chocolate isn\u2019t really in question, but it is important to point out that health benefits\u00a0are associated with specialty chocolates that have a high concentration\u00a0of cocoa solids and are minimally processed.\u00a0Milk chocolate and other sweeter chocolates undergo a \u201cdutching\u201d process that softens the bitter taste of the cocoa but also destroys many of the antioxidants.\u00a0The story was relatively clear on this point, so we\u2019ll award a satisfactory.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication.", "answer": 1}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of components of the Mediterranean diet is not in question.", "answer": 2}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nMost of the patients had an artery blockage greater than 70 percent.\nThe trial included patients who had suffered a stroke or a ministroke and those who were asymptomatic.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that surgery has long been considered the best treatment for obstructed carotid arteries, and that Medicare is considering expanding coverage to include stents. Readers can reasonably assume from these statements\u00a0that both\u00a0treatments\u00a0are widely available.", "answer": 1}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\n\u201cTogether, the three analyses appear to point toward a potential inverse association between multivitamin use with ASD with intellectual disability,\u201d say the authors.\nBut results from previous studies have been inconsistent, suggesting that other unmeasured factors (confounding), such as a mother\u2019s overall health and lifestyle, could also play a role.\nSo an international research team set out to assess whether nutrient supplementation during pregnancy is associated with reduced risk of ASD, with and without intellectual disability.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t mention availability of multivitamins, but we concede that supplements are as widely available as are drug stores.", "answer": 2}, {"article": "Soon after Zane relapsed, he and his father bumped into friends in a local doughnut shop who told them about a TV segment on CAR T-cell therapy.\nThe doctors assured the family that it was typical leukemia \u2014 and curable.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nBut her parents had hope that the transplant would keep her cancer at bay.\nIt seemed an equally promising target that could broaden the therapy\u2019s impact, researchers thought.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this therapy is experimental, and currently available only in trials.", "answer": 1}, {"article": "About 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is pending FDA approval and not yet available.\u00a0 ", "answer": 1}, {"article": "It was really stimulation in the gateway to the hippocampus - the entorhinal cortex - where we got the beneficial effect in terms of memory,\u201d Fried said.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nSuzanne Haber, a neuroscientist at the University of Rochester Medical Center in New York who was not involved in the study, said she was \u201cvery excited about the finding,\u201d but she cautioned that the treatment is very invasive, very expensive and unproven in Alzheimer\u2019s patients.\nThey also saw signs the treatment might have an effect on memory.\nIn a study published in the Annals of Neurology in 2010 researchers tested deep brain stimulation in six patients over the course of a year and found the treatment to be relatively safe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes how brain stimulation is now used to treat some patients with Parkinson\u2019s disease and other disorders, while making clear that more research is needed before anyone will know if it offers any benefits to people with Alzheimer\u2019s disease.", "answer": 1}, {"article": "Pain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Just like with cost, we don\u2019t get information about how available oral morphine is. However, it seems safe to assume it\u2019s widely available with a prescription.", "answer": 2}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nI should tell you that the new vaccine is not exactly a walk in the park.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\nMy only reaction beyond local soreness was an acid stomach for a day or two.\nThat\u2019s not all.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s available, and at least partly covered. The story makes this clear.", "answer": 1}, {"article": "\"We didn't expect that at all,\" Dackis says.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While modafinil is \u201clegal\u201d, it is still only FDA approved to treat narcolepsy and some cases of obstructive sleep apnea. The drug is also approved to treat shift work sleep disorders (i.e. the inability to adjust sleep hours due to overnight shift work), as this CNS stimulant has fewer side effects than caffeine or amphetamines. It is not yet approved to treat cocaine addiction. While the story explains the drug\u2019s current availability, it could have emphasized more clearly that the new use is still an unapproved use. Nonetheless, we give this a satisfactory score because of the cautions included in the story. ", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\n\u201cAlthough CTCA removes diagnostic uncertainty and halves the rate of subsequent heart attacks, quality of life can be negatively impacted in those who are worried about their health and are found to have nonobstructive coronary artery disease,\u201d Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story refers to CTCA as an available testing method.", "answer": 1}, {"article": "Drs.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests that some obstetricians already do \u2014 and more should \u2014 provide higher levels of fluids during labor.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here. For example, the story notes: \u201c[F]inding drugs like psilocybin effective is by no means the final hurdle to their widespread availability. None are currently in production, and no for-profit pharmaceutical company would likely invest millions of dollars to bring to market a pill intended effectively for one-time use.\u201d Well done.", "answer": 1}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\nKliman and the team focused on the nCyclinE molecular marker as a way to assess patients with recurrent pregnancy loss.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Progesterone is widely available, but what about the EFT? \u00a0We don\u2019t have any idea after reading this news release. We found no evidence relating to EFT in a review of clinical reproductive medicine guidelines.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It sounds like the devices are already available:\nOn the market less than two years, neither LifeVac nor Dechoker has published evidence of successful uses in humans.", "answer": 1}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\nA drink was defined as a very small glass of wine, a half pint of beer, or a small single measure of spirits, says study researcher Yvonne Kelly, PhD, of University College London.\nMothers were first asked about their alcohol use when the kids were 9 months old.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This does not seem to apply.", "answer": 0}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\nAdditional information, as well as a locator to find imaging sites offering the exams, can be found at\n\nAbout Hologic \n\nHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does mention that 3D mammography has been available since 2011 and includes a link to a website where people can enter their zip code to find locations that offer the additional screening test.", "answer": 1}, {"article": "The effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\n\u201cWhat we are hoping for with this device is to find a treatment for movement disorders where Levodopa, Parkinson\u2019s disease where Levodopa is not enough.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the device is experimental and, as a result, not available to the public. For comparative purposes, the story could have cited the cost of other devices that use the TENS technology.", "answer": 1}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nThe trial's researchers were careful to list indications of possible harmful side effects, such as a reduction in levels of HDL (\"good\") cholesterol, Califf said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We really never learn the status of the drug eprotirome.\u00a0 Is it approved?\u00a0 Is it used for anything else now?\u00a0 Readers may assume that it is because the headline already labels it as an \"alternative to statins.\"\u00a0 ", "answer": 0}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoctors may not change their approach anytime soon, however.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that nerve blocks are part of \"a common diagnostic technique.\" ", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Three graphs in, the story says, \"Many hospitals now use high-definition colonoscopes, which are sold by a number of companies.\" That\u2019s a vague sentence in a story that provides a lot more specifics in other areas. How many hospitals?\u00a0 Where?\u00a0 How likely is a reader to be in a situation where she/he is encouraged to have this type? ", "answer": 0}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nResearchers at Sheffield University found that in postmenopausal women during the first 10 years after diagnosis of breast cancer, the drug could reduce the risk of death by 18 per cent.\nA separate analysis by the same group, also published in The Lancet, looked at bisphosphonates, which are typically used for osteoporosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article describes aromatase inhibitors as \u201ca class of inexpensive, existing generics\u201d and bisphosphonates as drugs typically used to treat osteoporosis.", "answer": 1}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nAnd no one knows yet whether HPV testing actually catches cervical cancer at an earlier stage, or reduces deaths from the disease, compared with Pap tests.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nBut many women still do not get regular Pap screening, Whitlock pointed out.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The different testing methods are all widely available and that can be inferred from the story.", "answer": 1}, {"article": "Their parents filled out scales that measured their children's behavior, each child was tested for vigilance and concentration and their daytime sleepiness was measured and recorded.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that adenotonsillectomy is a common surgery in the U.S.", "answer": 1}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nOne of Blakeway's patients wrote an article for the magazine, Cookie, about her experience with acupuncture for her flagging sex life.\nBlakeway says she often has success combining acupuncture with Chinese medicine.\nThe greatest hope for a so-called \"female Viagra\" was a drug called flibanserin, but it was nixed by a panel of Food and Drug Administration experts on Friday, who said the drug didn't seem to really help women with sexual dysfunction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that an FDA panel voted against approval of flibanserin, an investigational drug for treatment of low sexual desire in women.\u00a0The availability of the alternative libido-boosting therapies discussed in the article isn\u2019t really in question, but the story does provide links to organizations which maintain lists of alternative health providers. \u00a0", "answer": 1}, {"article": ".\n\"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\nThe researchers performed biopsies on the 134 solid lesions they detected.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nSiegel and his colleagues used ultra-high-frequency ultrasound to image cancerous and benign skin lesions on 40 people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes no mention of the availability of elastography. The test is still under evaluation and is not widely available outside of research settings.", "answer": 0}, {"article": "\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nPeter Rothwell of Britain\u2019s Oxford University said that while taking aspirin carries a small risk of stomach bleeding, that risk was beginning to be \u201cdrowned out\u201d by its benefits in reducing the risk of cancer and the risk of heart attacks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that aspirin is widely used to relieve pain and reduce fever. Oddly, it does not highlight the use of aspirin by certain people to reduce their risk of heart attacks even though it was trials looking at those effects that provided the data for this analysis. While this story technically meets this criterion because aspirin is indeed available on store shelves and home medicine cabinets, the drug is specifically intended for use as an analgesic and, in certain individuals, to reduce the risk of certain heart-related problems; notwithstanding this one study, aspirin is not widely recognized or officially approved as a cancer prevention agent.\n", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article gives no indication when the discovery could be translated into a clinical screening tool but reviewers don\u2019t see that as a drawback in this story. The article is cautious about the implications of the finding and\u00a0 highlights experts calling for additional research so we can assume the tool is some years off.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is another close one. The story does explain the difference between hospitals and birth centers, but doesn\u2019t let readers know how common birth centers are in the U.S. Nor does it mention the availability of midwife services for home births, which can vary by state. However, the story does cite one U.S.obstetrics expert as saying that more birth centers could be established. Because the story addressed the issue, at least tangentially, we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nAll patients felt self-conscious wearing the device, Ritholz noted.\nRitholz's team found that people who were better at coping with the frustration of using the device were more successful at keeping their blood sugar under control.\nUsing this technology is still seen as a stopgap, however, while a biological solution to diabetes is sought.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One the one hand, the article tells us that the technology is emerging, the algorithm is still being developed, and the whole approach is still being researched in future studies. On the other hand, the article\u2019s tone and unbalanced quotes from investigators make the ultimate availability seem like a foregone conclusion, which it isn\u2019t after a 12-subject study. What\u2019s missing is at least some emphasis, ideally early, that this research is quite experimental at this point, with some discussion of the steps between this small study and the technology potentially going to market.\nThe article also takes until the third to last paragraph, after the discussion of the Ritholz study, to explain what an \"artificial pancreas\" actually is; burying that explanation and leading with an illustration of a real human pancreas does nothing but suggest to lay readers that an \"artificial pancreas\" is something like a prosthetic organ, instead of a computer link between extant devices. It could\u2019ve been clearer about how the \"closed loop\" technology is supposed to improve on the available devices. In fact, we\u2019re not sure that the description of the artificial pancreas as a single discrete \"device\" matches what was used in the study, which, according to the abstract, seems to have involved a glucose monitor, a computer, and a human being making adjustments to the patient\u2019s insulin pump.", "answer": 0}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nThe rats were pre-treated with the drug an hour before they were infected with parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nDr. Anne Moscona of Weill Cornell Medical Center in New York and colleagues tested varying doses of the drug, also known as DAS181, in lab dishes and on cotton rats, a species accepted by scientists for testing parainfluenza.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "       \n \nThe story makes it clear that this drug is not yet available. \n ", "answer": 1}, {"article": "All rights reserved.\nIf approved, Tykerb \u2013 known as Tyverb in Europe \u2013 will be used along with another drug that prevents hormones from making cancer cells multiply.\nApproval as an initial treatment likely would boost that sharply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The angle of the story is the drug company applying for approval in the US and Europe for its drug Tykerb as a first-line treatment for advanced breast cancer that is hormone sensitive..", "answer": 1}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nIt is by no means clear that doctors or patients will follow the new guidelines.\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\nStill, the new recommendations for Pap tests are likely to feed a political debate in Washington over health care overhaul proposals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Pap testing is assumed.\u00a0 ", "answer": 2}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nIn fact, the physician has wagered a few good bottles of champagne that none of three large randomized trials now underway will find proof of positive effects.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nUnfortunately, the lessons of history have shown repeatedly that many of these supplements that appeared to be very promising did not pan out in more rigorous testing.\u201d\n\nManson should know.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that vitamin D is widely available from food and supplements.", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this treatment is not yet available commercially.\nBut it would have been useful to include some information about whether and how someone might get enrolled in a clinical trial. Although it is unlikely that this program is ready to handle an influx of new cases, patients and parents might be desperate for any information on this question.", "answer": 1}, {"article": "Use our submission form, or ask @juliaoftoronto on Twitter.\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nSo, as this Cochrane review notes, it's impossible to draw firm conclusions on the effectiveness of the flu vaccine for those over 65 because the data is so biased and poor.\nBeyond public health measures (making sure you have good hand hygiene and avoiding the office when you're sick), the flu shot is the best medical intervention we have for preventing infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers answers to basic questions about the value of getting an annual flu shot.\u00a0 Those questions are obviously based on the fact that flu vaccines are usually readily available for those who want them.\u00a0 While some years present a possible shortage of vaccine, for most years, vaccination is determined by personal choice, rather than availability.", "answer": 1}, {"article": "\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nHe added, however, that meditation would work as well among whites and other populations.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indirectly addresses availability as it notes that live training in meditation from an instructor is necessary (a home video apparently won\u2019t cut it), and insurance won\u2019t cover the costs. It could provided some sense as to how easy it is to find qualified instructors in different areas (i.e. urban vs rural settings).", "answer": 1}, {"article": "The best performers included amitriptyline and escitalopram, while the worst included fluoxetine\u2014commonly sold under the trade name Prozac\u2014and reboxetine, which is not approved for sale in the U.S.\nAuthors of the study\u2014published yesterday in the Lancet\u2014believe many more people could benefit from antidepressant medication.\nApproximately 37 percent of these people received no treatment.\nAntidepressant drugs really do work, a major new international study has proven.\nWhile these results should reassure many people with depression that antidepressants can be effective, \u201cthis does not necessarily mean antidepressants should always be the first line of treatment,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A wide range of antidepressant medications have been on the market for decades, so there\u2019s no need to mention availability.", "answer": 2}, {"article": "2.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\n(Wender doesn\u2019t recommend the OTC tests that are available.)\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both colonoscopy and sigmoidoscopy have been available for years and the at-home screening tests mentioned in the story are said to be available through a patient\u2019s doctor\u2019s office. These details establish the methods\u2019 availability.\u00a0 It also quotes one source as\u00a0recommending against\u00a0the use of over-the-counter home screening tests for this disease.", "answer": 1}, {"article": "Digital tomosynthesis (DBT), or 3D mammography, does slightly better, detecting approximately 25 percent more cancers, or roughly 5 cancers in 1,000 women screened.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\nThe Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no mention of the availability of abbreviated breast MRI.", "answer": 0}, {"article": "\"I know that I can just sort of be on my sits bones, instead of a funny arch with my stomach pushed out or my back arched in some strange way,\" says Rodriguez\n\nJosephine Gray is Rodriguez's teacher and is a certified instructor in Alexander Technique.\nAfter a year, those who had massage were no better off.\nThose who had six Alexander lessons showed some improvement.\nBut finding a remedy for back pain can be a lot like a guessing game.\nBut there is evidence it can ease chronic low back pain over the long run.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In a major oversight, the article didn\u2019t mention that instruction in the Alexander Technique is not widely available in the United States. And that insurance companies in the U.S. generally do not provide reimbursement for this therapy.\n", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stresses that the type of pressure points used were specifically designed for this study, yet the story makes no mention of whether or not this method is available to any practitioners and if so, where to find them. ", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nCurrently fewer than one in five Americans eats the recommended two servings a week of fish.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nIn addition to the usual warnings about high mercury fish, Consumer Reports added marlin and orange roughy to the list.\nThe panel withheld a recommendation about tuna, second only to shrimp in popularity in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not address the availability of tuna fish. However, most readers can be expected to be familiar with canned tuna, which is widely available.", "answer": 2}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the study leader is now involved in an effort to replicate her results, which implies that the treatment regimen is not available at present. However, studies of social media and apps used to promote healthy behaviors\u00a0are ubiquitous, so\u00a0it might\u00a0have been useful for the reporter to explore the availability of this strategy compared to others on the market now.", "answer": 1}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\nBut guidelines then were more conservative, and in accordance with them, the subjects did not take the drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this test is readily available, and points out that it is generally not covered by insurance.", "answer": 1}, {"article": "New Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability at all. While many (or most) readers are aware that acupuncture therapy exists, they may be less familiar with how widely available it is. Readers may not be aware of pediatric acupuncture at all, much less pediatric acupuncture for children with ASD. Is there a special certification for pediatric acupuncture therapy? What about for pediatric ASD acupuncture therapy? The release doesn\u2019t tell us.", "answer": 0}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nThat's called the relative risk, and it seems alarming.\nThe concern is heightened by another, even rarer possible side effect \u2013 osteonecrosis of the jaw.\nThat's obviously a lot more benefit than risk.\nThat is, long-term users have a risk of about a tenth of 1 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the drugs as commonly available.", "answer": 1}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\nThis data is clinically significant.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\nBased on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.\"\n\"Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that the subjects in this study self-administered \u201cpulses\u201d each morning and evening, but readers are left wondering if this is done at a medical center or at home. If the former, do most hospitals and clinics have TMS machines? If done at home, how and where does one get a machine? Unclear.", "answer": 0}, {"article": "\"We're not training them on one skill, like doing crossword puzzles,\" she says.\nShe says the program increases involvement in so many different kinds of activities that retired people may not have engaged in otherwise.\nCarlson says it's not entirely clear which elements of Experience Corps account for the improved memory function and increased brain volumes.\nExperience Corps is a national program, however it can be costly and isn't available everywhere.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We don\u2019t believe that the availability of volunteering is an issue, but the story does note that this particular program \u2014 the Experience Corps \u2014 isn\u2019t available everywhere.", "answer": 1}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\nNow the test is being used to monitor for disease recurrence.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Early on the release states, \u201cNow the test is being used to monitor for disease recurrence.\u201d That sentence might confuse some readers into thinking the test is already in use. You have to read to the end to learn from a researcher\u2019s quote that \u201cOur next step is getting approval from the FDA.\u201d So that\u2019s a signal to readers that the test is not yet available, and may not be for some time. In addition, the comment about FDA approval doesn\u2019t give us any sense of the hurdles/obstacles that remain before the test would be validated for clinical use.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "What does \u201cclosing in on a blood test\u201d mean?\nWhat does \u201cnearing development of a blood test\u201d mean?\nDoes it mean a month? A year? A decade?\nAnd on what basis are these crystal ball predictions made?", "answer": 0}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\nChemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\nManipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the beginning of the 14th paragraph, the release notes that \u201cIt will take time [for JPC11] to progress from the lab to the clinic.\u201d Those are the only words that tell readers anything about where JPC11 is in the development process. The release does not tell readers what has been accomplished (some in vitro testing), what is next, what hurdles lie beyond that, or anything else pertaining to how long it may take for this to develop into a useful clinical tool. And there is no acknowledgment that it may never become a practical treatment.", "answer": 0}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nThey also wore accelerometers to track their physical activity during the rest of the day, to make sure the more intense exercisers weren't compensating with more time on the sofa.\nBottom line: All the exercisers improved, but the folks who did the best walked briskly for about 40 minutes five times a week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Walking and other forms of exercise are widely available for most. As noted above, however, some mention of the cost of a gym membership would have been helpful in a story like this.", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nIt is unlikely that people could get too much vitamin E from food.\nIn the current study, participants\u2019 primary vitamin E sources included vegetable oils, margarine and butter.\nExperts advise that adults consume no more than 1,000 mg of vitamin E per day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides a list of foods that are rich in this micronutrient.", "answer": 1}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nNPA is the leading trade association for the U.S. pasta industry.\nAnd now, even more good news: new research shows that pasta consumption in children and adolescents is associated with a better diet quality than that of children who do not eat pasta.\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable since it is generally known that pasta is inexpensive and widely available.", "answer": 2}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Lucentis was approved 4 years ago for another cause. ", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story is FDA approval of the drug.", "answer": 1}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nMore patients on the drug had the required improvement in symptom severity.\nThe company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\n\u201cWe knew the drug was safe and biologically active,\u201d H. Thomas Watkins, chief executive of the company, said in an interview.\n\u201cAnd we are in a field where we haven\u2019t even had anything fair.\u201d\n\nBenlysta, which is given by infusion once every four weeks, inhibits the action of a protein in the body called B-lymphocyte stimulator, which helps B cells in the blood respond to infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the drug Benlysta is currently being studied in clinical trials and is not available for use.", "answer": 1}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, the story makes it clear that the test could be performed now. That\u2019s technically accurate, and we\u2019ll award a satisfactory on that basis. However, we wonder how many general practice clinics are equipped both staff- and resource-wise to begin testing their patients. Even without the need for \u201cnew technology and expensive equipment,\u201d as stated in the article, one assumes clinics and hospitals much smaller than the Mayo Clinic (which developed the test procedures) would require at least some training and additional resources in order to introduce multi-part testing.", "answer": 1}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nWe also need to remember that in medicine, more often than not, we generally overestimate the benefits and underestimate the harms.\nAnd not all mass screening programs are bad.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that mammography is widely available.", "answer": 1}, {"article": "First published on July 1, 2008 at 12:00 am\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from this story whether both intensities of treatment are in general use and if not, which represented usual care. In addition,\u00a0treatment of kidney injury is complicated and it was not clear from this story how an individual would weigh in about treatment preference.\u00a0", "answer": 0}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nThe new test yields sensitive results in three hours.\nThe findings appear in the Dec. 28 issue of the Journal of the American Medical Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the new test is left as a mystery by this story.\nIs it experimental?\nIs it growing in use already?\nIs it in widespread use?\nWe\u2019re not told a thing about its availability or use.", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\nThe study is preliminary and doesn't prove cause and effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While statins are in widespread use, the story never emphasized that statins are not approved for treating psoriasis. ", "answer": 0}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nPhytochemicals, or bioactive food components, such as isoflavones in soy foods and glucosinolates in cruciferous vegetables may be the source of the benefit, researchers say.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nIndeed, in this study, Chinese breast cancer survivors ate more than twice as much soy and cruciferous vegetables.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that soy and cruciferous vegetables are found in basically all grocery stores so we\u2019ll rate this Not Applicable.\nHowever, there needs to be more recognition that people who live in \u201cfood deserts\u201d across the country \u2014 urban areas with limited access to affordable and fresh vegetables \u2014 cannot so easily access healthy food.\u00a0", "answer": 2}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses two products that are available for purchase. It also notes that people who have purchased one of these devices may not even be able to bring it on a flight.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cThe low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer.\u201d\n\nFindings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nFor these patients, the best curative option is SBRT, a specialized type of external beam RT that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that SBRT is a common choice for early stage lung cancer patients who are not candidates for surgery. But it\u2019s not clear how widely available this treatment is. This study was done \u201cacross four academic sites within Emory between 2010 and 2015.\u201d This implies that it may be available at academic institutions, but it doesn\u2019t state anywhere whether this is widely available in other treatment settings.", "answer": 0}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nThe third group got the usual care \u2014 medication and physical therapy.\nPeggy O'Brien-Murphy was among the study participants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Massage is widely available. The story states, \u201crelaxation massage is more widely available\u201d.", "answer": 1}, {"article": "All rights reserved.\nAmerica's favorite dietary supplements, multivitamins, modestly lowered the risk for cancer in healthy male doctors who took them for more than a decade, the first large study to test these pills has found.\nThat is less effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nCancer experts said the results need to be confirmed by another study before recommending multivitamins to the public.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins is not in question.", "answer": 2}, {"article": "\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nAs Robison\u2019s public profile rose \u2014 since \u201cLook Me in the Eye,\u201d he has divided his time between the car business and advocating on behalf of autism awareness \u2014 it disrupted his life on many levels.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that transcranial magnetic stimulation is available because it is used to treat depression. It is also clear from the story that TMS\u2019s use for treating autism is still not routine or even necessarily recommended.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Some of the language used suggests the technology is mature, \u201cNow, researchers at The Rockefeller University have developed an automated technology that combines imaging with digital analysis and machine learning to help physicians detect melanoma at its early stages.\u201d\nIt is not until the final\u00a0paragraph that the need for further research is noted.", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately states that Erbitux has recently been approved by the FDA", "answer": 1}, {"article": ".\nA new study shows that electro-acupuncture may be effective in providing some relief.\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nThe study is being published online in Menopause, the journal of The North American Menopause Society (NAMS).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention where or if electro-acupuncture is available to patients who desire such treatments.", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the LA Times story we reviewed, this story shows how widespread these implants are by explaining the scope of the study. \u201cThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\u201d Both stories could have benefited from a sentence about how likely hospitals in less populated areas are to have access to the implants and to have properly trained staff.", "answer": 1}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nThe study was presented at the Genitourinary Cancers Symposium.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explained whether capsules containing pomegranate extract are available.", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\n\"The effect of pulsed radiofrequency is fast and without adverse events.\"\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not made clear for readers if this is an experimental therapy, or if it is widely available.\nThe procedure is, in fact, a refined technique of an older procedure.", "answer": 0}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nBut, Brooks pointed out, that also means the breath test was wrong about one-quarter of the time.\nNow, a small pilot study suggests such a test could be developed.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this test won\u2019t be available any time soon.", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nThe current study investigated the impact of the combination of drugs on cardiovascular events.\nProfessor Babaeva's previous research showed that treatment with anticytokine drugs can decrease the activity of rheumatoid arthritis.\nThe effect was more apparent and developed earlier when patients were treated with a combination of anti-TNF\u03b1 and anti-IFN?, both at extra-low doses.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It can be safely assumed that the biologics mentioned in the study are on the market, but are the \u201cextra-low dose combination of two anticytokines\u201d readily available? We\u2019re not sure.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that we\u2019re talking about an off-label use of an available drug.", "answer": 1}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt could be that the whipworm larvae weren't prepared correctly.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nBack in Berkeley, Velasquez-Manoff thought he might one of the lucky ones.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that one person obtained worms in Mexico. Otherwise, there\u2019s no information about their availability. In fact, selling worms for therapeutic use is illegal in the U.S.\u2013this should have been mentioned.", "answer": 0}, {"article": "Food sources of vitamin D include milk, breakfast cereals and orange juice fortified with vitamin D, as well as some fatty fish, like salmon and mackerel.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe availability of vitamin D supplementation is really not in question. ", "answer": 2}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\nThe life-saving scans helped to spot those with heart disease so they could be given treatments to prevent heart attacks.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release just how available CTA scanners are.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that the study used powdered ginger, which it notes is used in cooking. People can deduce from this that powdered ginger is widely available.", "answer": 1}, {"article": "Get the facts.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that more than 178 million doses of the vaccine have been dispensed, meaning that it is readily available.", "answer": 1}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nThe current study reports clinical trial results for optimal use frequency.\nThis determined the most effective treatment frequency.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Even though the researchers advanced from theoretical thinking to animal and human trials there is no discussion of when the device might become available to patients.", "answer": 0}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nStent retrieval devices make that quick hospital transfer even more important, since the gadgets provide a crucial backup for tPA but are more tricky to use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these procedures can only be performed by highly-trained interventionists at specialized stroke treatment centers. The story emphasizes the importance of getting patients to these centers quickly. That\u2019s sufficient for a Satisfactory rating, but it would have been nice to know how many of these stroke centers there are throughout the country. And do most residents in the US live close enough to get to one within the magic short window?\u00a0\u00a0", "answer": 1}, {"article": "Rectal cancer affects some 2,000 men and women in Sweden every year.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\nA new study from Karolinska Institutet in Sweden shows that short-course preoperative radiotherapy combined with delayed surgery reduces the adverse side-effects of rectal cancer surgery without compromising its efficacy.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since these are existing treatments have already been in common use for many decades, availability is not an issue.", "answer": 1}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nThe study involved interns at Yale University and the University of Southern California.\nSarah Dalechek, a first-year psychiatry resident at that university, said her program requires two month-long rotations of 16-hour overnight shifts in an emergency room.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the study, \u201c..\u00a0used a free online program developed at the National Institute for Mental Health Research at the Australian National University in Canberra.\u201d\u00a0 but provides no additional information about general availability outside of the study.\nThe story should have mentioned the name of the online program that was used for the study in the case that any current residents may want to try it for themselves, or perhaps family members or friends\u00a0of current residents may want to suggest the program\u00a0if they come across the story.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Science doesn\u2019t just help to invent new products, it can push existing ones.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\n\u201cThe efficacy of our nutritional supplement was demonstrated by rigorous studies,\u201d said Nathalie Piccardi, of Laboratoires Inneov, who worked on the study.\n\u201cThe next step is to present this product to dermatologists,\u201d she told Reuters Health, noting it has already been launched in Europe and South America.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no question about the availability of the beauty product in question.\u00a0 The story states the company is preparing to \"present this product to dermatologists\" and that it \"has already been launched in Europe and South America.\" ", "answer": 1}, {"article": "Wu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\nCurrent mammography testing works well for detecting breast cancer in women over 50 with results of up to 95% accuracy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it is briefly noted that more research and evidence are needed, we think the tone of the article\u2014\u201dNew portable scanner for breast cancer\u201d\u2014misrepresents how soon the product could be available. Any such tool would have to run the gauntlet of clinical trials and evidence evaluation. As far as we can tell, this tool may not have even entered the arena yet. Clarity about the research status is necessary to create a realistic context, to give readers a sense of the timetable and likelihood for laboratory and the real world of hospitals or home screening.", "answer": 0}, {"article": "\u201cThe findings were exciting,\u201d she said.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nThe researchers found that the breathing exercise group\u2019s saliva had significantly lower levels of three cytokines that are associated with inflammation and stress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not an issue with breathing exercises. As one psychologist and book author quoted in the story says, \u201cBreathing is massively practical.\u201d\nHowever, the story misleads readers a bit by implying that the benefits of breathing exercises can be achieved in just a couple of minutes. In fact, proponents espouse at least 20 minutes of controlled breathing on a daily basis, often over several months, to achieve benefits.", "answer": 2}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beta blockers are called \u201ccommon heart drugs\u201d in the story and are thus generally understood to be widely available. Beta-blockers first came on the market more than 50 years ago and their use has become widespread as researchers found more applications for this class of drugs. Generic versions are available, making them some of the most affordable prescription drugs.", "answer": 1}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nThe DNA stool test methods were developed at the Mayo Clinic.\n\"Detection of these important types of precancer by stool DNA testing offers promise in our efforts to more effectively and affordably prevent colorectal cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At one point the story says the test is \"under development.\"\u00a0 In another place it says the methods \"were developed.\"\u00a0 No where is it clear if this is a method that is currently available. ", "answer": 0}, {"article": "Recently, he says, urologists \"have begun to realize these criteria are not adequate.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nWhen these errors occur, the study says, doctors most often conclude the cancer is less serious than it really is.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that clinical staging is \u201cwidely used\u201d and that 10 years ago the American College of Surgeons \u201cdecreed that doctors should use these types of clinical staging tests to help decide how to treat cancers.\u201d", "answer": 1}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nAge does seem to reduce our endurance and strength to some extent, Dr. Harridge said, even if we exercise.\n\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\nOf course, this study is based on a single snapshot of an unusual group of older adults, Dr. Harridge said.\nMany older people require at least 7 seconds to complete the task, with those requiring 9 or 10 seconds considered to be on the cusp of frailty, Dr. Harridge said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, finding time and places to ride a bicycle is not always as easy at it sounds. But we\u2019ll rate this not applicable since we\u2019ve already dinged the story for this issue above under \u201ccosts.\u201d", "answer": 2}, {"article": "Robotic surgery replaces a surgeon\u2019s hands with ultra-precise tools at the ends of mechanical arms, all operated by the surgeon from a console.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nHu and his team analyzed surgery data from a national government database to see if the costlier robotic surgeries were cost effective with extra benefits over older techniques.\n\u201cI think the take home message is that robotic (surgery), looking at our study, had certain beneficial outcomes compared to open and laparoscopic procedures,\u201d said study leader Jim Hu at Brigham and Women\u2019s Hospital in Boston.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of all 3 surgical approaches studies \u2013 while not explicitly described \u2013 could be inferred from the study details reported.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges in the third-to-last paragraph that \u201cfurther clinical research is needed to see if the findings can be applied in a clinical setting.\u201d That\u2019s good\u2013but we would have liked to seen this detail much higher. Also, we would have liked to seen some discussion of how many more steps are in the process\u00a0to develop an effective blood test for clinical use.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nI also had three sensor catheters slip out and require early replacement, which would be especially annoying to anyone paying the $35 that each sensor costs; I wasn\u2019t, because MiniMed had supplied everything free for testing, but everybody else will, since the sensors are not yet covered by insurance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the \u201cParadigm Real-Time\u201d combination insulin pump and glucose sensor was approved by the FDA, implying it is available to consumers. It was a little confusing to hear one man\u2019s story about traveling to another city for a \u201ctest-period\u201d in which the manufacturer paid for supplies, which sounded a bit like a study scenario or a special promotional deal. And, it\u2019s still not clear whether this is available everywhere or only at certain locations. But, the article also tells readers that insurance won\u2019t pay for the supplies as yet (even though the anecdotal story-teller felt it was worth it to him to start paying this), adding to the idea that if one wanted to pay the out-of-pocket expense, one could obtain this device. ", "answer": 1}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\nThe inexpensive CRP test could identify those with higher inflammation, who might be candidates for taking a drug like canakinumab.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that no one is suggesting the drug at present for routine use, and that at present the drug is not cleared for use in heart disease patients.", "answer": 1}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nscan, he said, radiologists should put the findings in context.\nAnd often the result was surgery \u2014 orthopedic surgeons do more meniscus surgery than any other operation.\nAfter Dr. Modic and others scanned hundreds of asymptomatic people, they learned abnormalities were common.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly MRIs, CT scans and other scans are widely available.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn about one French doctor using this approach in London.\u00a0 We are given no sense of whether anyone else is doing this or where. ", "answer": 0}, {"article": "Sitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nParticipants in the study familiarized themselves with the workstations during one visit.\nActive Ideas LLC, which offers the HOVR device used in study, funded the research.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The HOVR device used in the study is commercially available, as the news release says. A search online shows that it can be purchased both from the company website and from Amazon.", "answer": 1}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis new approach places them right on the scalp.\nSince then, the technique has been refined.\nCould this could work for all kinds of pain?\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment states that transdermal direct current stimulation (TDCS) is still in clinical trials. ", "answer": 1}, {"article": "It is much rarer in people who take a lower-dose bisphosphonate (such as Actonel, Boniva or Fosamax) for osteoporosis.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nAfter six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It could\u2019ve been more explicit about the drug\u2019s current availability via prescription.\u00a0We also don\u2019t applaud the comment that Forteo is \u201cnot yet\u201d approved for this indication. It could\u2019ve been worded in a less presumptive manner.", "answer": 1}, {"article": "U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials.\nThe drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\nWhen the injections stopped, many in the study relapsed.\nThe drug has no street value or abuse potential.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Information about FDA approval of the drug\u2014in 2006 for alcohol dependence and in 2010 for opioid users\u2014is included in the story.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t touch on availability, but availability isn\u2019t really an issue here. The babies received various treatments at different hospital centers. Active interventions ranged from ventilation and chest compressions to intubation.", "answer": 2}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\nPlans for a clinical trial of low-dose lithium for PD patients are in early stages.\nThe Buck Institute is the U.S.'s first independent research organization devoted to Geroscience - focused on the connection between normal aging and chronic disease.\nCitation: The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that lithium is currently available and used for psychiatric illness. Given that the drug is available, it\u2019s conceivable that desperate patients will seek treatment with lithium based on these findings \u2014 which is why it\u2019s all the more important to carefully qualify the results in the headline.", "answer": 1}, {"article": "ASDs mainly affect a person\u2019s social interaction and communication, with symptoms that can include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty adapting to new environments.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\nScientists said their research found a link between ASD and damage to proteins in blood plasma.\nThis may help us improve the diagnosis of ASD and point the way to new causes of ASD.\u201d\n\nThe research has been published in the journal Molecular Autism.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions two damaged proteins, in particular, which researchers found in higher concentrations of the blood of children with ASD, than in blood of children in the control group. We\u2019re not told if the tests for these proteins are routine or highly specialized. Exactly what was found in the urine isn\u2019t mentioned. Therefore, the availability of both the blood and urine tests is unclear.", "answer": 0}, {"article": "All rights reserved.\nAdding the gene test put 100 men into that category, said another study leader, Dr. Matthew Cooperberg of UCSF.\nThe gene test shifted about half of the men into either a lower or a higher risk category.\nConversely, the test also suggested some tumors were more aggressive than doctors had believed.\nGenomic Health has not published any results on the prostate test, another thing that makes doctors wary.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that one test goes on sale today and that another recently came on the market. And it raised the questions about whether availability/use will be limited if there isn\u2019t evidence it leads to better care or saves lives.", "answer": 1}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The premise of the story is that this is a treatment that is \u201cincreasingly being used.\u201d The story says, \u201cReiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain.\u201d The story never goes on to prove that this is a method that is increasingly being used. All we are given are a few examples of treatment centers that do offer Reiki and then this: \u201cOther centers don\u2019t offer Reiki, citing insufficient evidence. \u201cThere isn\u2019t a good evidence base for its utility in cancer care as of yet,\u201d says Lorenzo Cohen, a professor in the departments of general oncology and behavioral science at M.D. Anderson Cancer Center in Houston.\u201d\nReaders across the country may be left wondering just how widespread this practice is.", "answer": 0}, {"article": "Furthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nOther studies have demonstrated beneficial health and quality of life effects from yoga interventions in cancer patients.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nMost yoga participants reported a sense of well-being at the end of each class, and upon finishing the yoga program and concluding their study involvement, many patients requested and received an at-home practice routine to fit their needs, Ben-Josef said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the near ubiquity of yoga classes is well-known, it is not clear how available Eischens yoga classes may be. The release also doesn\u2019t tell us what distinguishes Eischens yoga from other forms of yoga.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nEven a year or two of a better diet appears to have the power to affect survival rates, he said.\nThe findings paint a surprising picture of American health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Except possibly for food deserts, healthy foods are generally available. The story makes the case that widespread consumption of healthier foods has had broad public health benefits.", "answer": 1}, {"article": "Doctors can try to treat glioblastoma with surgery to remove the cancerous cells, and blast them with radiation and chemotherapy.\nCurrently, most people diagnosed with the condition die within two years.\nThe animals dosed only with the stem cells developed tumors.\nA vaccine against the Zika virus could one day be used to fight the deadly brain cancer that claimed the life of Senator John McCain, according to a study in mice.\nThe condition recently made headlines as the disease that killed senator John McCain at the age of 81.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear this treatment isn\u2019t available for use in humans.\nThe story could have put the findings into clearer perspective if it noted that availability for human is at best 5 to 7 years in the future\u2013and actually may never come to pass.", "answer": 1}, {"article": "If all it requires is to take a closer look at the images, how can we ignore it?,\" he said.\nFuture prospective trials are needed to see what the prognostic significance of breast arterial calcification might be.\n\"This information is available on every mammogram, with no additional cost or radiation exposure, and our research suggests breast arterial calcification is as good as the standard risk factor-based estimate for predicting risk,\" Hecht said.\nThis study is being published simultaneously online in JACC: Cardiovascular Imaging.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The digital mammogram is widely used and available and neither the release or the study seem to be calling for additional testing beyond what is already taking place. So while availability is not specifically addressed, it\u2019s pretty evident from the release that such testing is widely available.", "answer": 1}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n\"Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release mentions that the intervention is part of the SI! program \u2014 but it doesn\u2019t establish what that is or whether it\u2019s something that the wider public has access to. One might presume that the program is used only in a research setting at present, but we don\u2019t know that for sure, and the release should have made this clear.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies, correctly, that Botox injections are widely available. ", "answer": 1}, {"article": "But there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that consumer tablet computers are widely available so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The surgically reconstructed knees and the conservatively treated joints experienced similar (and high) levels of early onset knee arthritis, a common occurrence after an A.C.L.\nTwenty-five percent of those in the physical therapy group eventually tore their meniscuses.\nThe second group received only physical therapy, with the option to have the operation later.\nThe authors of the study are less sure.\nTwenty-three subjects of that group did eventually have the operation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that ACL\u00a0surgery and physical therapy are available.", "answer": 1}, {"article": "Dr.\nBoth tests would be less expensive than colonoscopy, and potentially more effective.\nDr. Ahlquist said he was very pleased with the new results, especially the 64 percent detection rate for precancerous polyps, since these are best targets for intervention.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\nThe trial will be completed in 2012 and the test, if approved, should be available shortly thereafter.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nMM36 is expected to be the 2nd topical PDE4 inhibitor in the market after the potential approval of Anacor Pharmaceuticals' crisaborole product.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\n\"Based on the results of this study, it appears that MM36 could address an important unmet need in dermatology.\"\n\"We believe these Phase 2 results demonstrate compelling evidence of MM36's capacity to be a leading topical PDE4 inhibitor and are aggressively developing MM36 for atopic dermatitis in the US.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although industry-sponsored releases must avoid \u201cforward looking\u201d predictions about future drug approval, the release would have added useful information if it had noted whether this phase 2 trial would be followed by phase 3 trials. As it stands there is no way to gauge if or when this product will be available.\nIt seems overly optimistic to make this statement based on a phase 2 study: \u201cMM36 is expected to be the 2nd topical PDE4 inhibitor available in the US and may offer unique benefits for patients suffering from AD.\u201d ", "answer": 0}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nAnd they might want to offer the test to people with milder symptoms who want to know whether they are developing the devastating brain disease.\nDoctors might want to use the test in cases where they want to be sure of the diagnosis.\nThey note that it is not reliable enough \u2014 results can vary by lab \u2014 and has been studied only in research settings where patients are carefully selected to have no other conditions, like strokes or depression, that could affect their memories.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story states that spinal fluid tests for Alzheimer\u2019s are commercially available. However, the test used in the study that was the focus of this story used chemicals that are available only to researchers. Also, as a review of spinal fluid biomarkers for Alzheimer\u2019s disease noted, almost all the testing done to date has taken place in careful controlled research labs and there is substantial work to be done to ensure that different labs could produce consistent results.\n\u00a0\nReference:\nLessons from Multicenter Studies on CSF Biomarkers for Alzheimer\u2019s Disease\n http://www.sage-hindawi.com/journals/ijad/2010/610613.html ", "answer": 0}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nAfter a few days have passed, though, there is little or no chance of preventing heart damage.\nThe study showed there was no need for the procedure.\nThe ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nBut many doctors open the artery anyway, thinking it may still have long-term benefits and prolong the patients\u2019 lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the story that this is a widely used procedure.\u00a0", "answer": 1}, {"article": "Moffitt is the No.\nThe researchers previously developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells.\nResearchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no information on where to get this treatment, whether it\u2019s widely available, and if not yet available when it might be approved as a treatment for breast cancer.", "answer": 0}, {"article": "In mild cognitive impairment, a person's changes in thinking are noticeable to himself, friends, or family.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nIt also doesn't change the very limited treatment choices.\nAlzheimer's is just one possible cause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nRight from the start this story makes clear that the revised definition of Alzheimer\u2019s disease \u201cwon\u2019t change how the vast majority of people are diagnosed. It also doesn\u2019t change the very limited treatment choices.\u201d", "answer": 1}, {"article": "\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nMore testing showed she had anal cancer.\nFurther testing showed the baby was healthy.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the availability of these new tests is not specifically addressed, the story does note that \u201cprenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders\u201d \u2014 implying that the new tests are one such option. We\u2019ll award a Satisfactory on that basis. The story could also have noted that the new test are recommended by the American College of Obstetrics and Gynecology for some women. Usually they are offered for women over 35 or with other risk factors for a fetus with Down syndrome or certain other chromosomal abnormalities.", "answer": 1}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nLilly has filed for approval of the drug by the U.S. Food and Drug Administration.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug has been FDA approved and is available for patients with psoriasis and that Lily has applied for FDA approval for use in patients with psoriatic arthritis as well.", "answer": 1}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nIt can cause throbbing pain in the head.\nThey were developed in conjunction with the American Headache Society.\nMany migraines can be prevented by taking medication every day.\nEach headache may last from four hours to two days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these drugs are widely available.", "answer": 1}, {"article": "Women between 40 and 49 were screened every two years, and women 50 to 74 were screened roughly every three years.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\n\u201cOur results indicate that in 1,000 women screened for 10 years, three breast cancer deaths would be prevented,\u201d Duffy said, adding that most of the deaths prevented would have occurred more than a decade after the screening had started.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of mammograms is not in question. \u00a0\n", "answer": 2}, {"article": "\"Nothing happens,\" he told Stahl.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story quotes one of the developers of the device as saying that the start of human clinical trials could begin within two to four years. Viewers are not given a clear explanation of the rudimentary stage of the investigation of this device.\n Viewers would also likely be confused about the distinction between initiating clinical trials and actually bringing a product to market. When the researcher says they would \u201csucceed,\u201d he is apparently referring to initiating trials; but it is likely that many viewers believed he was predicting that ultimately the treatment would be successful.", "answer": 0}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAnd it can boost older people's strength and balance.\nThe sport is also associated with good mental health and improving the overall health of those with disabilities.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Golf is widely available worldwide. But as suggested in the release it may be prove unaffordable for many.", "answer": 1}, {"article": "Dr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\nA new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.\nThe George Institute is now looking at strategies to maximise uptake of the study results.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s implied (but not made very clear for readers) that the pill is in trials and, therefore, not commercially available.", "answer": 1}, {"article": "But if we tailor treatments to the individual biology of the tumor and characteristics of the patient, we'll get the best results,\" Wolf says.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nAs part of a Specialized Program of Research Excellence, or SPORE, grant, the team was already maintaining long-term follow-up data on patients.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nThe non-responders can be referred immediately for surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this approach to determining the best course of treatment could be implemented at any point \u2014 there are no new technologies or drugs involved. But the release does a particularly good job of addressing this, since it highlights a relevant challenge: \u201cThe induction approach can be done anywhere, but requires intense collaboration among surgeons, medical oncologists and radiation oncologists. All three must be involved to assess the patient and refer to the appropriate therapy.\u201d Communication between all of the practitioners involved in the case of any given patient can be a significant challenge, and is well worth mentioning.", "answer": 1}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nOthers have such high cholesterol that taking statins alone is not enough.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no discussion of when and where these new drugs may be available to the average person, or at what price. A statement that these drugs are not currently FDA approved, and a description of what\u2019s needed to attain that approval, would be appropriate.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not gather or report any information about the number of individuals already trained in Philadelphia or in other major cities (such as Seattle) where records have long been kept related to\u00a0bystander CPR training and use. And while it says the need to train more people is \u201cacute,\u201d it doesn\u2019t tell us whether the problem is a lack of available training sessions or the failure to take advantage of those opportunities. The lack of data contributes to the reader\u2019s misunderstanding of the urgency for CPR training.", "answer": 0}, {"article": ".\nThe prospective Phase II single arm, multi-center study tested the safety and effectiveness of injectable contraceptives in 320 healthy men ages 18 to 45.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\nDuring this period known as the efficacy phase of the study, the men continued to receive injections every eight weeks for up to 56 weeks.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The study does not give the impression that injectable hormones for men are readily available. In fact, it quotes a researcher stating that \u201cmore research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception.\u201d\u00a0 However, it could have mentioned that in addition to safety issues, there are other barriers to making male injections widely available. For example, a drug company would have to be willing to make it and sell it at an affordable price.", "answer": 1}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\nHowever, it\u2019s important not to think of them as cheat days.\nThe dieters ate enough calories to maintain their weight during the off period.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was pretty clear from the article that this was a small study and the absence of any specific information about the diet itself would lead a reasonable reader to conclude that this one is not commercially or otherwise available. That doesn\u2019t mean people won\u2019t try to devise one on their own.", "answer": 2}, {"article": "For more on dietary supplements, visit the Office of Dietary Supplements of the U.S. National Institutes of Health.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nEach patient ultimately cycled through each section.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that green coffee bean extract is sold online.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force recommendations state that most women begin mammography at age 50.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nSince the new guidelines lean heavily on knowing breast cancer risk, doctors need to redouble their efforts to make sure risk assessments are done for women in their early 40s, they concluded.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that breast cancer risk assessments are not normally performed in women ages 40-44 years, but didn\u2019t elaborate if breast cancer risk assessments are routinely completed in doctor\u2019s offices or if a woman would need to see a specialist to have one.", "answer": 0}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\nThe three trials demonstrated how hard it is to test things once they\u2019re in widespread use.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beyond establishing general availability of the different approaches. the story provided this important big picture context:\u00a0 \u201cThe three trials demonstrated how hard it is to test things once they\u2019re in widespread use.\u201d", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the same meeting, other researchers reported that they have new clues about how DNA characteristics can help predict colon cancer risk.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nThe new test, a next-generation stool test known as a DNA methylation test, detects tumor-specific alterations or methylations in the DNA in the cells shed into the stool from cancerous or precancerous lesions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that a clinical trial may begin in 2011 and said that the lead researcher believed that \u201cif all goes well the test could be available soon after that.\u201d", "answer": 1}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\n\u201cWill these peptides actually induce tolerance in people?\nThe particles are about 200 times smaller than the thickness of a human hair.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment being tested in mice and says, perhaps optimistically, that trials in humans would be at least two years away.", "answer": 1}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions medications like aspirin, naproxen, and ibuprofen, all of which are currently available (and available without a prescription, although this is not explicitly stated). ", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did not explicitly note the general availability of bypass surgery and angioplasty/stent, there are sufficient hints to allow the reader to appreciate that they are routinely offered.", "answer": 1}, {"article": "\"But I will say that I don't know of any study looking at acupuncture and vision.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\nThere are studies based on symptomatic things such as pain, and I think there's pretty good evidence that it does have benefit in that respect.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story\u00a0notes that acupuncture is more widely accepted in certain geographical areas than others, it doesn\u2019t convey how difficult a time people would have finding a skilled acupuncturist\u00a0across broad swaths of the country. This is especially important considering that the treatment was given 5 times a week and would be impractical\u00a0if significant travel time was required.\u00a0It also should have mentioned accreditation for\u00a0acupuncturists and how to choose a\u00a0practitioner.", "answer": 0}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\nShe had heard a lot of positive feedback from people who had undergone hip replacement surgery at her hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers examples of hospitals currently offering \u201csame-day\u201d hip replacements. If anything the story understates the availability of the procedure.\nHowever, the story could have been more clear about who this procedure is most available to, since this won\u2019t be the right option for some people. For example, if they don\u2019t have help at home, or if they live far from the hospital.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\nGeorge said he hopes that by better understanding where TMS should be delivered and by figuring out the best dose and duration of treatment, success rates closer to those of ECT might be achieved.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that TMS is approved by the FDA for the treatment of depression, but this characterization may give the impression that TMS is more widely available than\u00a0is actually the case.\u00a0TMS is cleared\u00a0for use only in patients with major\u00a0depression who don\u2019t get better after treatment with an antidepressant medication.\u00a0Also,\u00a0while we couldn\u2019t locate data as to how widely available TMS treatment is, it is safe to say that most practitioners don\u2019t have a TMS device in their office.\u00a0Obtaining access to the machine\u00a0and trained operators is likely to be a challenge for\u00a0many patients,\u00a0especially those in rural areas. The story should have pointed out these important restrictions on the treatment\u2019s availability. \u00a0", "answer": 0}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\nEmmanuel Mignot of Stanford University, who wrote a commentary on the study in the same journal, said the findings show promise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that Merck has applied for FDA approval of a similar drug.", "answer": 1}, {"article": "\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThey plan to continue modifying the test to improve the urine sensitivity to that of the cervical tissue samples.\nThe researchers tested the value of these genes as markers using 214 cervical cell samples collected from women undergoing Pap smears at Hospital Dr. Hernan Henriquez Aravena in Chile.\nNewswise \u2014 Johns Hopkins Medicine specialists report they have developed a urine test for the likely emergence of cervical cancer that is highly accurate compared to other tests based on genetic markers derived directly from cervical tissue.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "All depends on a reader\u2019s understanding of the nature of a proof-of-concept study.\u00a0 This urine test is not yet available, but that will be murky to non-specialists unless the term is defined. Reading between the lines it is evident that further testing is needed before it can be used as part of routine care. ", "answer": 0}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThrough a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind\u00ae platform to accurately identify patients who are resistant to androgen receptor (AR)-targeted therapies and who should instead switch to chemotherapy.\nThe blood test called, Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 is commercially available in the U.S. through Epic Science's partnership with Genomic Health, Inc. (NASDAQ: GHDX).\nThis is the second blinded, multi-center clinical utility validation study utilizing the nuclear-localized AR-V7 test.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release said the test, Oncotype DX AR-V7 Nucleus Detect, is commercially available in the U.S. However, it didn\u2019t clarify whether it\u2019s FDA-approved for testing patients with prostate cancer. Because the test is not currently covered by Medicare, for those patients the test may only be available as an out-of-pocket expense.", "answer": 1}, {"article": "Feb. 20, 2017.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\nAccording to Amin, improved technology has allowed wrist access to become a viable route to the coronary arteries, even for complex cases, and should be considered for more patients.\nNewswise \u2014 Hospitals can improve patient care and reduce costs associated with coronary angioplasty if cardiologists perform more of these procedures through an artery in the wrist and if they take steps to discharge such patients on the same day, according to a new study led by Washington University School of Medicine in St. Louis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It clearly conveys\u00a0that the lower cost variants of angioplasty\u2014use of the wrist artery and same-day discharge of the patient\u2014are available but little utilized among Medicare patients. The use of the wrist entrance method appears very low (9%) among Medicare patients.", "answer": 1}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nPart of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.\nHIF-2 inhibitors, which grew out of research begun more than 20 years ago at UT Southwestern Medical Center, work by interfering with processes that fuel the growth of cells.\nIn 2014, the first HIF-2 inhibitor, an oral drug known as PT2385, entered clinical trials in patients with advanced or metastatic renal clear cell carcinoma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear this is an experimental drug, so experimental it doesn\u2019t even have a name, just a codename: PT2399.", "answer": 1}, {"article": "\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nBut taking into account some of these heterogeneities across studies, the team's meta-analysis summarizing data from 19 trials found potential beneficial effects of flavanol-rich cocoa on cardiometabolic health.\nThe meta-analysis in the Journal of Nutrition, an assessment of the combined evidence from all 19 RCTs, focused on whether consumption of flavanol-rich cocoa products was associated with improvements in specific circulating biomarkers of cardiometabolic health as compared to consuming placebos with negligible cocoa flavanol content.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that cocoa flavanols can be obtained from various sources including drinks (cocoa) and dark chocolate. It\u2019s common knowledge that these are widely available. It\u2019s less widely known that dietary cocoa flavanol products are available and it would have been useful to point that out.", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes the widespread availability \u2013 too widespread \u2013 of stenting quite clear.", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0This story makes it known that the vaccine is still in the testing phase and is not yet available.\u00a0 ", "answer": 1}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty\u00a0surrounding their actual efficacy.\nThe story goes the extra distance in mentioning that the dose of medicine used in this study in long longer employed. It also states that other, similar, medicines are used more commonly now. Finally, it goes on to say that studies are underway evaluating these other drugs.", "answer": 1}, {"article": "Rates are rising, in part because tanning became fashionable.\nNew data about to be released to a meeting of cancer specialists shows that 40 percent of the patients who have been taking the drug are still alive three years later.\nThe drug, called Keytruda, takes a new approach to treating cancer by stopping tumor cells from cloaking themselves against the normal, healthy immune system response.\nIt was bad enough for 8 percent of patients that they stopped taking it.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0makes it clear that Keytruda was approved by the FDA in 2014 and is commercially available.", "answer": 1}, {"article": "\u201cIt felt as though my head was a cement block,\u201d Kaufman told NBC News.\nThe aim of the medication is to stop a migraine before it even starts.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\n\u201cIt's not a pill, it's an injection that stays in the system for a long period of time and is continuously blocking that CGRP mechanism of migraine.\u201d\n\nResults from several pharmaceutical trials are expected either later this year or in early 2018.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes availability:\nResults from several pharmaceutical trials are expected either later this year or in early 2018. If approved by the FDA, the drug could be available in 2018.", "answer": 1}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\n\u201cThere is very little deficiency of folic acid in North America,\u201d Deborah O\u2019Connor, a nutrition researcher who was not involved in the study, told Reuters Health.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nDuring the study, Sweden did not fortify foods, nor did kids use a lot of supplements.\nThe new study is among the first to examine whether folate is tied to school achievements, according to Dr. Torbjorn Nilsson of Orebro University Hospital and his colleagues.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that folic acid is one of the \u2018B\u2019 vitamins and that at least in the US, is found in fortified foods.\nThe story could have also mentioned that folic acid is a common ingredient in multivitamin formulations.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the surgery is widely available and increasing in frequency. It also indicates\u00a0the populations for which it is currently recommended. ", "answer": 1}, {"article": "In addition, we saw that several smaller brain areas actually started to grow in response to training,\" says Ulrik Dalgas.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nDrugs can counter this development, but we saw a tendency that training further minimises brain shrinkage in patients already receiving medication.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release provides too little information on what types of exercises are included in the training program and whether they require coaching and monitoring from a trained physical therapist. Is this training widely available for MS patients? We can\u2019t know from this release.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0implied that there are plenty of places to get these procedures, but lack of evidence and insurance coverage, as well as concerns by the FDA, are standing in the way of availability.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the laser approach \u201chit the US market in February.\u201d", "answer": 1}, {"article": "According to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will come away from this story understanding that DBS is not currently available for the treatment of high blood pressure \u2014 and probably won\u2019t be any time soon. That satisfies the\u00a0main expectation of this criterion, so we\u2019ll award a satisfactory. The story could have provided more\u00a0information about which\u00a0conditions DBS\u00a0currently is used\u00a0to treat.\u00a0(DBS is\u00a0FDA-approved for the treatment of\u00a0several movement disorders, including Parkinson\u2019s disease, and is sometimes used to treat other conditions, including chronic\u00a0pain and depression.) It also could have explained that DBS is\u00a0available primarily at large urban medical centers,\u00a0and that doctors\u2019 experience with the procedure can vary widely.", "answer": 1}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\nJust 15 minutes after the surgery Ekstadt can already see better and can make out a line in the eye chart that she couldn\u2019t decipher before.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both of these implants are approved by the FDA, the story tells us, but are they widely available? We are assuming that surgeons need training in how to handle these new devices. Is surgery only available in large metropolitan areas? Is it performed in a doctor\u2019s office? We wish the story had included some details on this.", "answer": 0}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\nIn addition to this study, researchers will present the latest in Alzheimer's disease at the AACC Annual Scientific Meeting & Clinical Lab Expo, including:\n\u2022 New research explores using the level of angiotensin-converting enzyme (ACE) in the brain and spinal cord as a biomarker for neurodegenerative diseases, including Parkinson's disease and AD.\n\"This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.\"\n\"Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies\" (A-180)\n\nSession Information \n\nRegistration for the AACC Annual Scientific Meeting is free for members of the media.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release should have offered a timetable on availability or next steps in development.", "answer": 0}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not describe whether the AMH test is available or not.", "answer": 0}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nTurns out there\u2019s a simple blood test that could tell her.\nShe\u2019s grateful to the Baby Deadline Test for giving her that option.\nFor Alyssa Gold, the AMH test was a wakeup call.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the blood test is pretty common in fertility clinics, and we\u2019re informed that the patient in the story took the test at her regular ob/gyn\u2019s office. That\u2019s enough information to give readers\u00a0a general sense of the test\u2019s availability.", "answer": 1}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\nOf these patients, 84 had been ablated, sixteen were being treated with drug therapy, and three had implanted devices that served as a quality control check.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\nWe call them \"highly motivated patients,\" said lead author Monica Pammer, PA-C, a physician assistant in Electrophysiology at the Hospital of the University of Pennsylvania.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It seems obvious that the drugs being studied are on the market and fully available, but it is hard to definitively know this. The news release tells us the drugs are \u201cnovel\u201d but doesn\u2019t name them.", "answer": 0}, {"article": "For example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\n\"Pre-hab\"\u2014building up strength before the surgery\u2014is just as important as re-hab afterward, they say.\nThat said, some patients are determined to push the envelope, and some doctors give their blessing.\nThe biggest variable is patients themselves.\nPatients say that regaining function after surgery requires enormous mental and physical effort.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that knee and hip replacement are widely available across the United States.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nAll of the herbs were screened for quality, and the M-Y mixture was deemed to meet Chinese safety standards.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The description of the herb mixture\u2019s availability is good enough for a satisfactory. The story says that \u201cfinding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\u201d\u00a0 The story could have noted that ephedra\u2019s use remains\u00a0legal in traditional Chinese medicine (the application being discussed in this story), but patients may\u00a0only obtain the medicine through\u00a0a Chinese medicine practitioner.", "answer": 1}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At the end of the story, it mentioned that what it earlier referred to as \u2018a combination pacemaker and defibrillator device\u2019 had had it use expanded by \u2018U.S. regulators\u2019 to include mild heart failure.", "answer": 1}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that various smartphone apps are available that provide this training and that the author picked the only one that had any supporting scientific evidence.", "answer": 1}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of how widespread is the use/availability of knee braces in general or of the studied knee brace specifically. ", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n- None of the treatments had an impact on general quality of life, such as the ability to do activities of daily living, emotional health and energy or vitality.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t say so explicitly but it\u2019s generally understood that all the treatments studied are widely available and applied.", "answer": 2}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One could argue that statins are among the most popular drugs and, therefore, their availability is widely known. But this story should have at least mentioned the specific statin being studied and the fact that they are only available by prescription.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was clear that the MSMB test reported on is investigational and not currently available.", "answer": 1}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\nIn the study, investigators injected cardiosphere-derived cells, a specific type of stem cell, from newborn laboratory rats into the hearts of rats with an average age of 22 months, which is considered aged.\nCapricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development.\nThe study was published today by the European Heart Journal.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a close call. We rate this criterion Satisfactory since the release includes some cautionary language about the availability and applicability of cardiac stem cells, stating that they \u201ccould someday help reverse the aging process in the human heart\u201d and \u201cWe have much to study\u2026\u201d\nHowever, the release also mentions that the cardiac cells \u201chave been used in other human clinical trials,\u201d but doesn\u2019t clarify whether it\u2019s been approved by the FDA for use in humans.", "answer": 1}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nWhat's more, the apparent protective impact of both prescription and nonprescription NSAIDs on skin cancer risk seems to be stronger the longer someone takes them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of NSAIDs isn\u2019t in question.", "answer": 2}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Botox injections are so widely available in the U.S. that this doesn\u2019t merit much discussion. The article accurately identified the regulatory status of Botox injections for chronic migraines.\n\n \n", "answer": 1}, {"article": "Atrial fibrillation also increases the risk for dementia.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nDuring the study, more than 26,000 of the 440,000 participants, all with atrial fibrillation, were diagnosed with dementia.\nThey also found that the sooner people started taking blood thinners after their diagnosis of atrial fibrillation, the lower their risk for dementia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It may seem fairly obvious that these anticoagulants are widely prescribed.\u00a0 The fact that the study was among community-dwelling people who were already taking these treatments reinforces their availability.", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nTwo co-authors, not including Melby, have ties to the soy industry.\nThe study had no industry funding.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of soy supplements is not in question.", "answer": 2}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nMarban and colleagues developed a technique in which they loaded cardiac stem cells with microscopic bits of iron.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story barely implied that there is still work to be done before this is available for people.\u00a0 Barely satisfactory. ", "answer": 1}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\nEven at that point, the study shows, GFAP levels might be higher than normal and therefore might indicate TBI and need for further tests.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies these tests aren\u2019t yet available, chiefly by calling them \u201cpromising.\u201d However, the story should have made it explicitly clear whether these tests are something patients could ask for now.", "answer": 0}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n\u201cIn Australia, low-fat diets are often recommended for improving heart health and they are still perceived as being healthy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the news release doesn\u2019t discuss availability, it\u2019s generally understood that items for a dairy-supplemented Mediterranean diet can likely be found in many grocery stores.", "answer": 2}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the NanoKnife is \"currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla.\" It later says, \"The NanoKnife, which is also available in five hospitals outside the U.S., has so far been used to treat about 300 cancer patients world-wide.\"", "answer": 1}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nThe medication is not available yet, but the U.S. Food and Drug Administration is reviewing it for possible approval, the researchers said.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the drug is \u201cbeing developed\u201d and has been submitted to the FDA for approval.", "answer": 1}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nResearchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes the drug is experimental. ", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nBut some also want Sarepta to make the drug available to more patients on a compassionate basis even before approval.\nIt would also represent a success, after decades of setbacks, for the technology eteplirsen uses, called antisense, which is a way of turning off specific genes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is investigational and not available at the present.\u00a0 It also provided some additional insight, \u201cBut Ms. McNary said Sarepta had refused to provide the drug to Max\u2019s 13-year-old brother, Austin, who could not be in the trial because he already could not walk.\u201d\u00a0 \u201cMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials. \u201cThat would be the quickest path to insolvency,\u201d he said.\u201c", "answer": 1}, {"article": "\u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nThe Awair app is free to download, but each device costs $199 dollars.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the device and app are already available.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not describe the availability of Actos.", "answer": 0}, {"article": "Normally, cells in the pancreas work to release insulin, a hormone that can process sugar and either send it to cells that need it for energy or store it as fat for future energy needs.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nThe current study takes that work a step further and shows that it\u2019s possible to actually reverse the disease in people who have been diagnosed.\nAll of the people had been diagnosed with type 2 diabetes in the six years preceding the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story outlines the components of the diet, but not whether an interested could access such care from a physician. Given the extremeness of the diet \u2014 the first months are limited to 850 calories a day and education and therapy adjuncts are brought in to help people maintain their progress when switching from the liquid nutrition to real food, not to mention a mountain of evidence on the difficulty of maintaining weight loss \u2014 it seems likely that health care providers\u2019 help would be necessary.", "answer": 0}, {"article": ".\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that abemaciclib is now being tested in trials designed to \u201cdefine the role of abemaciclib in cancer care.\u201d However, it never explicitly states that these trials might end up finding that the drug does not ultimately provide sufficient advantages over existing treatments. Its reference to \u201cinvestigational\u201d in the title and text may be enough to give some readers the tip-off that this drug won\u2019t be available anytime soon. However, we recommend news release writers make it abundantly clear when a drug is only available as part of research trials and that it is not available for use in routine clinical practice. The statement, \u201cFDA decision to grant breakthrough therapy designation,\u201d may lead a reader to think this could be available for use more broadly.", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Same comment as the \u201cCompare Alternatives\u201d section.", "answer": 2}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that estrogen and progestin pills remain available, but are to be prescribed with awareness of risk/harm tradeoffs.\u00a0 ", "answer": 1}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nAsiedu is also working to automate the screening process.\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\nThis work was supported by the National Institutes of Health (1R01CA195500, 1R01CA193380).\nHealth providers -- or even women themselves -- are able to capture images of the cervix using the rounded tip of the device to manipulate its position if necessary.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not clearly state that the device is currently unavailable. Savvy readers may glean this from the description, but a more direct statement and discussion of the steps involved before the device can be commercially produced and used would have been helpful.", "answer": 0}, {"article": "GlaxoSmith Kline and Eli Lilly supplied Lovaza and Raloxifene, respectively.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nManni added that, with obesity-related cancers on the rise, the findings could have implications beyond breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the omega-3 fatty acid supplement used in this study, Lovaza, is FDA approved and requires a prescription from a physician.", "answer": 1}, {"article": "\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says the red sage is \u201cwidely used\u201d in traditional Chinese medicine. That conveys that it\u2019s easy to get.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news brief does not mention availability, but most readers will know where to find calcium and vitamin D supplements.", "answer": 2}, {"article": ".\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThat was the first thought on Davis' mind as he returned to consciousness in the recovery room, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes no mention of how widely available cryotherapy is.", "answer": 0}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nLanser says it can be tricky to diagnose food allergies.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nIn Jula's case, her allergists at National Jewish Health in Denver, Colo., repeated the standard allergy blood tests last summer.\nBut diagnosing allergies can be tricky, and kids can outgrow them, too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss how easy it is to find an allergy clinic that does oral food challenges, but it does refer parents to allergists for further discussion.", "answer": 1}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nSo you have to at least expect that sometime in your life, you are going to need a reoperation.\nBut now the Food and Drug Administration has evaluated the safety of the second generation of silicone implants and the results are mixed.\nAs it turned out, Knecht's implants had leaked; a biopsy found silicone in her lymph nodes and in her lungs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beginning with a clear description of silicone breast implants\u2026banned in 1992, back five years ago with a concurrent FDA evaluation process\u2026the article does an excellent job of establishing availability.", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although never explicity stated, the widespread availability of angiotensin inhibiting drugs can be inferred from the story. ", "answer": 1}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\n\"These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,\" the study team noted in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question. The story would have been better if, like some of the other stories we reviewed, it had pointed out that aspirin is approved for use as an anagesic and, for certain people, to reduce the risk of some cardiovascular events, but it is not currently recommended for cancer prevention.", "answer": 1}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nBurgoon\u2019s group has persuaded some states to bar physical therapists from the practice.\nAbout 6,000 have taken courses in dry needling in the past few years, Zylstra says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story essentially lets people know that this is something that is becoming more popular but that not very many physical therapists are trained in it yet.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nPatients with the condition say it\u2019s time for better treatments.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nStudies have found it significantly reduces heavy menstrual bleeding and decreases the thickness of the endometrium by six months.\nThe drug has been available in Europe and Canada for several years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes the new drug could be available in the US next year. The drug is already available in the US for another indication but is packaged in doses that are much larger than those used for fibroid treatments.", "answer": 1}, {"article": "But at least we know it can be done.\"\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\nEarly in the decade, more than 20 prominent researchers wrote an open letter to the journal Science urging the federal government to cancel the Thai trial because the vaccine was so unpromising.\nThe vaccine, a complicated mixture of six \"prime\" and \"booster\" shots, reduced a person's risk of becoming infected by about one-third compared with people getting placebo injections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental stage of the vaccine research is clear from the story, as when it states: \nThe vaccine is not licensed or being produced in large amounts. It is unlikely \u2014 but not impossible \u2014 that any country would consider it effective enough to be used as a public health measure against HIV. ", "answer": 1}, {"article": "In the study, 15 men and 15 women drank either 17.6 ounces of a beet juice beverage consisting of about three-fourths beet juice and one-fourth apple juice, or a placebo juice.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of beet juice is not in question.", "answer": 2}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nHe points to other research under way with ivacaftor combined with another drug that could help people with the most common mutation of cystic fibrosis.\nAbout 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation, and the average person with the disease dies before age 40.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough the story is clear that this drug is not yet available, it includes a claim that it could be on the market next year. The manufacturer recently applied for FDA approval, but the drug has not been reviewed, so any claim about availability is mere speculation.", "answer": 0}, {"article": "\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nIf the uncovered mechanism indeed works in the prevention of breast cancer in high risk patients, this could possibly be used to prevent breast cancer in general.\nCareful phase III clinical trials are now needed to confirm the efficacy in humans.\nA multinational research effort now made the discovery that RANKL is also the main driver of BRCA1 mutation-driven breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Denosumab has been on the U.S. market as an approved treatment for certain types of osteoporosis since 2010 and tumors since 2013 but it is not approved as a preventative breast cancer treatment. The release may be misleading readers by suggesting it is \u201calready approved.\u201d\u00a0 The completion of safety and efficacy trials in humans are years down the road. The release doesn\u2019t even say that advanced trials are planned, only that they\u2019re \u201cneeded.\u201d", "answer": 0}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS\n\n\n\nFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nNone of the patients in the HF10 therapy group experienced paresthesia.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nIdentifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these complex patients.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release if this device is approved and available. It appears that it is.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nOutcomes in this study were at least 50 percent lower than those reported in previous studies,\u201d Sacco and Rundek write.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes from the NEJM editorial, which says \u201cthe widespread, systematic implementation of specialized TIA units across multiple sites, countries, and continents can make a difference in the care of these patients.\u201d\nHowever, it\u2019s not clear how common these specialized TIA units are. Can they be found in any major hospital? Only in big cities or especially large medical centers? Only in a few of those medical centers? And is the \u201caggressive\u201d treatment mentioned in the headline only available at these specialized TIA units, or can it be found in most emergency rooms? Readers are left in the dark on this one.", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nFor the first time in Wisconsin, a research team will test a personalized cell therapy to treat a common and serious complication in bone-marrow transplant patients.\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\nThe Wisconsin Partnership Program at the UW School of Medicine and Public Health announces four new awards through its Collaborative Health Sciences Program.\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both medications in this combination therapy (AChEI and Lupron) are currently available. We appreciate that the\u00a0news release\u00a0ends by noting the preliminary nature of the findings, and the uncertainty as to whether additional studies of this combination will be conducted. But unfortunately, the release\u2019s mischaracterization of the results will likely overpower this note of caution.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that \u201cthe findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\u201d The story says nothing about all the hoops that remain for a finding to go from the lab to the drug store. Nor does it mention anything about the many cancer \u201cbreakthroughs\u201d that have failed to fundamentally alter the rates of cancer incidence or mortality over many decades.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a small pilot study and the release states, \u201cMany issues will need to be addressed, but we predict routine screening for CP in the near (<10 years) future.\u201d\u00a0 While many may differ with whether the \u201cnear future\u201d is define by \u201cfewer than 10 years,\u201d the release gets credit for spelling this out.", "answer": 1}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\n\"In addition to the clinical outcomes, we now have a clear understanding of the mechanisms through which limited BCG vaccine doses can make permanent, beneficial changes to the immune system and lower blood sugars in type 1 diabetes.\"\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\nFaustman's team first reported in 2001 that inducing TNF production could cure type 1 diabetes in mice, but since TNF dosing is toxic in humans, clinical trials have utilized BCG for its ability to elevate TNF levels safely.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that BCG has been used for \u201calmost a century\u201d to prevent tuberculosis.\n(Of note, it\u2019s also been used for non-invasive bladder cancer.)", "answer": 1}, {"article": "\"We, in the scientific community, often give strong advice based on flimsy evidence,\" he said.\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\nThat could mean that fat in the diet may have a small effect, Dr. Rossouw said, perhaps in some subgroups of women or over a longer period of time.\nBut the Mediterranean diet has not been subjected to a study of this scope, researchers said.\nSome medical specialists emphasized that the study did not mean people should abandon low-fat diets.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story failed to point out how the study goals were different than the existing FDA dietary guidelines. FDA calls for percentage of calories from fat (20-35%) with saturated fat (< 10%) and trans fats (limited intake) as compared to the study goals of less than 20% of calories from fat with no target set for either saturated or trans fats. Why were the study goals different than federal agency guidelines? The audience should be told. ", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nIt did find enough new data to recommend for the first time against screening for older men.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\n\"There is this idea that more is always better, and if a test is available we should use it,\" said Howard A. Brody, a professor of family medicine at the University of Texas Medical Branch at Galveston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that it was about routine screening of men for prostate cancer. \u00a0As the story lead with \"The blood test that millions of men undergo each year\", it accurately indicated that this test is readily available.\n\u00a0", "answer": 1}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nBut it did reveal it was important to further study hormones and the body\u2019s endocrine system, and how they relate to mental illnesses like anxiety and depression, he said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, since the story speculates aggressively about the clinical usefulness of this test, we\u2019d like to see some information about how widely available it is. Is this a highly specialized test available only to researchers? Could consumers request such tests from any lab? Such context is important to help readers understand the impact of this research.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Tough call here. The story says that DXA scans are \u201cavailable at a growing number of spas, hospitals and doctor\u2019s offices.\u201d But the statement comes from a company representative. What does \u201cgrowing number\u201d mean? Are you likely to be able to find this outside of posh resorts and major cities?", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.04.026.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\nThe ring is designed to be replaced by an ophthalmologist every six months.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The new release accurately states says the device \u201cmay one day be a promising option\u201d for patients who struggle with administering eye drops, though it could give readers a better sense of just how far off that day might be. The news release says a phase 3 trial of larger groups of patients is expected to begin this year, but does explain how long that would take or mention the lengthy process required to win approval from the Food and Drug Administration.", "answer": 1}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nOther LA BioMed researchers who participated in the study were: Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Jeby Abraham, Michael A. Fahmy, Christopher Dailing, Ferdinand Flores and Sajad Hamal.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\nThe study involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The Aged Garlic Extract\u00a0mentioned in the release is readily available at health food stories and other venues.", "answer": 1}]